Zovirax

Zovirax is an antiviral medicine built around acyclovir, used for herpes virus infections where suppressing viral activity early can shorten symptoms and reduce new lesion formation. Cold sores are a type of viral skin infection, and the classic “fever blister” on the lip is usually herpes labialis caused by herpes simplex virus type 1 (HSV-1). Genital herpes is more often linked to HSV‑2, yet both HSV‑1 and HSV‑2 can affect either location.

Zovirax does not remove herpes from the body permanently. It reduces viral replication during an outbreak, so your immune system can regain control faster.

Two practical points matter in real life: treatment works best when started early, and hydration matters more than people expect with oral acyclovir therapy.

Active ingredient: acyclovir (tablet strength varies by prescription, commonly 200 mg, 400 mg, or 800 mg per tablet). Excipients may include tablet fillers and binders such as cellulose derivatives, starches, and magnesium stearate; exact composition depends on the specific tablet strength and manufacturer batch.

Used for treatment and suppression of herpes virus infections: herpes labialis (cold sores), genital herpes, and varicella-zoster infections such as shingles. It may also be prescribed for chickenpox in selected patients and for prevention of recurrent outbreaks in people with frequent recurrences or reduced immunity. Use only as prescribed and start treatment as early as possible after symptom onset.

• Route: oral (tablets)
• Herpes labialis (cold sores): 400 mg 5 times/day (about every 4 hours while awake), with or without food, for 5 days.
• Genital herpes, initial episode: 200 mg 5 times/day (about every 4 hours while awake), with or without food, for 10 days.
• Genital herpes, recurrent episode: 200 mg 5 times/day for 5 days, or 400 mg 3 times/day for 5 days; with or without food.
• Suppressive therapy (recurrent genital herpes): 400 mg 2 times/day, with or without food; duration commonly 6–12 months with periodic reassessment.
• Shingles (herpes zoster): 800 mg 5 times/day (about every 4 hours while awake), with or without food, for 7–10 days.
• Chickenpox (varicella): 800 mg 4 times/day, with or without food, for 5 days (use depends on age and clinical need).
• Timing notes: space doses evenly during waking hours; drink water with doses to support hydration.

Zovirax is used for herpes simplex virus infections such as cold sores (herpes labialis) and genital herpes, and it is also used for herpes zoster (shingles), which is caused by varicella-zoster virus (a different herpes virus family member). Herpes zoster is a type of condition where viral reactivation causes a painful, often one-sided blistering rash, and early antiviral treatment can reduce new lesion formation and shorten viral shedding in many patients ^[2].

A key difference is topical versus systemic need:

• Cold sores are often localized and may be treated topically in mild cases.
• Genital herpes is typically treated with oral antivirals, since the infection involves mucosal tissue and deeper nerve reactivation.
• Herpes zoster usually requires oral antiviral therapy, started early, because the virus affects nerve pathways and can drive significant pain.

Zovirax can reduce symptoms, but it does not eradicate herpes from the body. Recurrence prevention may require episodic treatment (at outbreak start) or suppressive therapy in people with frequent recurrences.

Both options target cold sores, yet they work in different ways. Zovirax (acyclovir) is a topical antiviral agent in cream form and an antiviral tablet for systemic therapy; Abreva (docosanol) is a topical, non‑prescription cold sore treatment that interferes with viral entry/fusion at the skin cell membrane rather than blocking viral DNA replication.

The practical takeaway: for frequent or severe herpes outbreaks, systemic antiviral therapy is often chosen by clinicians, while topical approaches are more suited to mild, localized cold sores and very early use.

People usually don’t struggle with the idea of antivirals; they struggle with timing and habits.

• Starting late: waiting until lesions crust over before beginning oral therapy.
• Under-hydrating: taking tablets with little fluid, raising kidney stress in susceptible patients.
• Dose clustering: taking several missed doses close together, which increases side effects without improving control.
• Assuming “no new sores” means non-contagious: viral shedding can still occur around outbreaks.
• Using oral tablets as a substitute for trigger control: sun exposure and lip trauma can still set off recurrent cold sore outbreaks.

In day-to-day prescribing, doctors tend to use Zovirax tablets when the outbreak pattern is frequent, lesions are extensive, or the infection is genital herpes where systemic therapy is standard. In clinic follow-ups, one consistent observation is that patients who start treatment at the first prodrome (tingling, burning, nerve pain) report shorter and less intense episodes than those who wait for clear blisters.

I also see a predictable trade-off: acyclovir works, but the dosing schedule can be demanding. People who miss doses often assume the medicine “failed,” when the real issue is irregular spacing and late initiation.

Another pattern: for herpes zoster, clinicians push for early initiation because later treatment may still help, yet the benefit on new lesion formation and viral shedding is strongest early in the course.